CompletedPhase 2

Biweekly TPF Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of Head and Neck

58 participantsStarted 2014-03-01

Plain-language summary

This study aimed to assess the efficacy and safety for biweekly TPF as induction chemotherapy for locally advanced head and neck cancer

Age range20 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. The patient has histopathologically or cytologically confirmed diagnosis of stage 3 or 4 squamous cell carcinoma of the oral cavity, larynx, oropharynx or hypopharynx.
✓. The patient has local advanced, and no distant metastatic, and unresectable disease.
✓. The patient has measurable or valuable disease. 4 Age ≥ 20 years.

✕. The patient had previous chemotherapy or radiotherapy for squamous cell carcinoma of head and neck.
✕. The patient has uncontrolled disorder(s), serious illness or medical condition(s) is/are not be enrolled to study that be confirmed by investigator.
✕. Previous or concurrent malignancy except for basal or squamous cell skin cancer and/or in situ carcinoma of the cervix, or other solid tumors treated and without evidence of recurrence for at least 3 years prior to the study.
✕. Peripheral neuropathy \> Grade 2.
✕. The patient is pregnant or breastfeeding.

Response rate after induction chemotherapy

Timeframe: through study completion, an average of 1 years

NCT IDNCT04397341

SponsorChina Medical University Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2016-08-30